Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Extended Treatment Time With Bevacizumab Does Not Confer PFS Benefit in Ovarian Cancer

November 26th 2022

Increasing the duration of bevacizumab treatment in the frontline setting did not improve progression-free survival for patients with advanced ovarian cancer.

FDA Seeks to Restrict Rucaparib to Second-line Maintenance Therapy in Recurrent Ovarian Cancer

November 18th 2022

The FDA has asked Clovis Oncology to limit use of rucaparib to second-line maintenance therapy for patients with recurrent ovarian cancer harboring BRCA mutations.

Key Data Highlights in Ovarian Cancer

November 17th 2022

The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.

Treatment of Rare Tumors in Ovarian Cancer

November 17th 2022

Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.

FDA Approves First IHC Companion Diagnostic for Mirvetuximab Soravtansine in Ovarian Cancer

November 15th 2022

The FDA has approved the VENTANA FOLR1 RxDx assay, the first immunohistochemistry companion diagnostic test to help identify patients with epithelial ovarian cancer who are eligible for treatment with mirvetuximab soravtansine-gynx.

FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer

November 14th 2022

The FDA has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for the treatment of select patients with folate receptor α–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

FDA Requests Restriction of Second-line Maintenance Niraparib Indication in Ovarian Cancer

November 14th 2022

At the request of the FDA, GlaxoSmithKline plc will restrict the second-line maintenance indication for niraparib to only the population of patients with recurrent ovarian cancer whose tumors harbor deleterious or suspected deleterious germline BRCA mutations.

Defining Clinical Benefit in Oncology Trials Is Not as Simple as Some May Believe

November 14th 2022

A core component of any type of therapeutic research is to enhance clinical benefit.

PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer

November 10th 2022

The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor.

Investigative Therapies in Recurrent Ovarian Cancer

November 10th 2022

A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.

Clinical Trial Data on Antibody-Drug Conjugate Treatment for Ovarian Cancer

November 10th 2022

Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.

Mirvetuximab Soravtansine Leads a Cascade of ADCs Under Development in Ovarian Cancer

November 7th 2022

Kathleen N. Moore, MD, MS, discusses the clinical implications of the potential FDA approval of mirvetuximab soravtansine, observations from other antibody-drug conjugates under investigation in clinical trials, and the rationale of examining PARP inhibitor–based combinations in ovarian cancer.

Antibody-Drug Conjugates in Ovarian Cancer Treatment

November 4th 2022

Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.

The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer

November 4th 2022

Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.

BRCA Mutations, HRD Status Drive PARP Inhibitor Selection in Ovarian Cancer Maintenance

November 3rd 2022

Bobbie J. Rimel, MD, discusses how PARP inhibitors are deployed across different treatment settings of ovarian cancer, the recent market withdrawal of PARP inhibitors in later-line indications, and ongoing research efforts at Cedars-Sinai Medical Center for patients with ovarian cancer.

PARP Inhibitor Resistance in Ovarian Cancer Treatment

October 27th 2022

Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.

Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment

October 27th 2022

A look at the maintenance treatment strategies for advanced or metastatic ovarian cancer.

Time Required to Address Scientific Questions Generates an Information Dilemma

October 26th 2022

One of the more perplexing issues surrounding scientific questions is the extended time required to provide an answer. Even once a well-considered and vetted conclusion is obtained, an additional interval of time may be required to modify or reverse the answer because of new, relevant data.

Exploration of ADCs Highlights the Drive for Personalized Treatment in Ovarian Cancer

October 26th 2022

Rodney Rocconi, MD, discusses the continued exploration of antibody-drug conjugates in patients with ovarian cancer, biomarkers and agents under investigation in the space, and the ongoing research being conducted at the O'Neal Comprehensive Cancer Center.

Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian Cancer

October 24th 2022

Paul A. DiSilvestro, MD, discusses the long-term survival benefit of olaparib maintenance in advanced BRCA-mutated ovarian cancer.